000144150 001__ 144150
000144150 005__ 20240229112618.0
000144150 0247_ $$2doi$$a10.1007/s00066-019-01482-1
000144150 0247_ $$2pmid$$apmid:31240346
000144150 0247_ $$2ISSN$$a0039-2073
000144150 0247_ $$2ISSN$$a0179-7158
000144150 0247_ $$2ISSN$$a1439-099X
000144150 0247_ $$2altmetric$$aaltmetric:77928133
000144150 037__ $$aDKFZ-2019-01699
000144150 041__ $$aeng
000144150 082__ $$a610
000144150 1001_ $$0P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aBostel, Tilmann$$b0$$eFirst author$$udkfz
000144150 245__ $$aStability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy : Results from a large multicenter cohort.
000144150 260__ $$aHeidelberg$$bSpringer Medizin$$c2019
000144150 3367_ $$2DRIVER$$aarticle
000144150 3367_ $$2DataCite$$aOutput Types/Journal article
000144150 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1578475647_31681
000144150 3367_ $$2BibTeX$$aARTICLE
000144150 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144150 3367_ $$00$$2EndNote$$aJournal Article
000144150 500__ $$a2019 Dec;195(12):1074-1085
000144150 520__ $$aThis retrospective study aimed to evaluate the stability and fracture rates of osteolytic spinal bone metastases (SBM) in elderly patients following palliative radiotherapy (RT) and to derive prognostic factors for stability and survival.A total of 322 patients aged at least 70 years received palliative RT at two major German academic medical centers or at the German Cancer Research Center. Stability assessment was based on the validated Taneichi score prior to RT and at 3 and 6 months after RT. The survival time following RT was assessed, and prognostic factors for stability and survival were analyzed.Prior to RT, 183 patients (57%) exhibited unstable SBM and 68 patients (21%) pathological fractures. At 3 and 6 months after RT, significant recalcification and stabilization were evident in 19% (23/118) and 40% (31/78) of surviving patients, respectively. Only 17 patients (5%) experienced new pathological fractures following RT. Tumor histology was found to significantly influence stabilization rates with only breast cancer patients exhibiting increased stabilization compared to patients with other histologies. The median survival time and 6‑month survival rates following RT were 5.4 months (95% confidence interval 4.4-7.2 months) and 48%, respectively. The patients' performance status was found to be the strongest predictor for survival after RT in this patient cohort; further factors demonstrating a significant association with survival were the application of systemic treatment, the number of SBM and the primary tumor histology. To analyze the influence of age on survival after RT, study patients were stratified into 3 age groups (i.e., 70-74 years, 75-79 years, and ≥80 years). The subgroup of patients aged at least 80 years showed a strong trend towards a worse survival time following RT compared to younger patients (i.e., 6‑month survival rate 39% vs. 51%; p = 0.06, log-rank test).Prognostic factors influencing overall survival such as performance status and histology should guide the choice for palliative RT for SBM. Strongly hypofractionated RT regimes may be advisable for most elderly patients considering the overall poor prognosis in order to reduce hospitalization times.
000144150 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000144150 588__ $$aDataset connected to CrossRef, PubMed,
000144150 7001_ $$aFörster, Robert$$b1
000144150 7001_ $$aSchlampp, Ingmar$$b2
000144150 7001_ $$aSprave, Tanja$$b3
000144150 7001_ $$aAkbaba, Sati$$b4
000144150 7001_ $$aWollschläger, Daniel$$b5
000144150 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b6
000144150 7001_ $$aMayer, Arnulf$$b7
000144150 7001_ $$aSchmidberger, Heinz$$b8
000144150 7001_ $$aRief, Harald$$b9
000144150 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b10$$eLast author
000144150 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-019-01482-1$$n12$$p1074-1085$$tStrahlentherapie und Onkologie$$v195$$x1439-099X$$y2019
000144150 909CO $$ooai:inrepo02.dkfz.de:144150$$pVDB
000144150 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000144150 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000144150 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000144150 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000144150 9141_ $$y2019
000144150 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144150 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144150 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144150 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2017
000144150 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144150 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144150 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000144150 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144150 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144150 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144150 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000144150 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144150 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x0
000144150 980__ $$ajournal
000144150 980__ $$aVDB
000144150 980__ $$aI:(DE-He78)E050-20160331
000144150 980__ $$aUNRESTRICTED